Ribocure Pharmaceuticals represented at European Liver Congress, EASL, in Vienna

Li-ming Gan, CEO at Ribocure Pharmaceuticals, is for the first time showing our preclinical PoC data at the EASL meeting this week. The study was conducted using our mouse surrogate molecule in an in-house developed mouse model of NASH with elevated hepatic HSD expression. HSD17B13 is a genetically identified target strongly associated with liver steatosis […]

Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial.

Ribocure Pharmaceuticals AB receives Authorisation for a Phase II clinical trial to evaluate efficacy and safety of its novel siRNA asset for treatment of chronic hepatitis B infection. Ribocure Pharmaceuticals AB, a pioneering Swedish biotech company and the international research center of Ribo Life Science Ltd, focused on development of cutting-edge RNA therapeutics, is delighted to […]

Both building and Ribocure team grow!

In June we move into the entire fifth floor of the GoCo Clinic building and established a unique “from bench-to-bed” set-up with an R&D department, a Ph2 clinical trial unit (Ribocure Clinic) and an in vitro human cell lab. 

GoCo House Lunch Launch

GoCo House Lunch Launch took place and we were there from Ribocure Pharmaceuticals to meet our future neighbours and potential collaborators. The excitement is high to expand our business and for the transition in to our new facilities in GoCo Clinic in June!

World’s first siRNA-based FXI silencing agent

World’s first siRNA-based FXI silencing agent enters clinical development – an important step toward a new generation of anti-thrombotic therapies for our patients! Suzhou Ribo announces the first siRNA-based FXI targeting anti-thrombotic agent (RBD4059) to receive HREC approval for first-in-human study in Australia.On February 6th, 2023, Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to […]

Visit at GoCo and Gothenburg by one of the founders

Visit at GoCo and Gothenburg by one of the founders, Dr Hongyan Zhang, from the parent comany. Impressed and inspired by the vibrant GoCo environment, Swedish efficiency and quality in construction and design. Full endorsement for our establishment and further expansion at GoCo Clinic!

First tour at the future office

First tour at the future office. A near 1000 sqm facility with R&D, lab and clinical trail unit will be out future work place. 

Ribocure Pharmaceuticals AB establishes in GoCo Clinic

Ribocure Pharmaceuticals AB establishes in GoCo Clinic- putting Sweden in the spotlight within oligonucleotide therapeutics GoCo Health Innovation City can now happily announce that Ribocure Pharmaceuticals AB will move in and open a clinical trial unit at GoCo Clinic – where both patient care and research will be conducted. The ambitions are high and with […]

Privacy Policy (Integritetspolicy)
Your privacy is important to us. Ribocure Pharmaceuticals AB respects your privacy regarding all data we may collect from you on our website, www.ribocure.com.
We collect data/information to make contact and establish and maintain a relationship. We collect this information in a fair and legal way with your awareness and consent, as stipulated by GDPR (General Data Protection Regulation). We also let you know why we collect it and how it will be used.
The data that is stored are the fields that each submission form contains. We save the data for as long as is necessary with regard to the purposes of the processing. We always base the collection of personal data on consent.
You have the right to request information about what personal data we have stored about you. To do this, contact the Data Protection Officer (DPO). You also have the right to request correction or deletion of your personal data at any time.
Your continued use of our website will be deemed as acceptance of our privacy and personal information practices. If you have any questions about how we handle user data and personal information, please contact us.
Contact information to the Data Protection Officer (DPO):
Data Protection Officer
Ribocure Pharmaceuticals AB
Vetenskapens gränd 11
431 53 Mölndal
E-mail: dpo@ribocure.com